Sarepta Therapeutics, Inc.
SRPTSarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.
Drugs in Pipeline
7
Phase 3 Programs
3
Upcoming Catalysts
4
Next Catalyst
Aug 5, 2026
7dMarket Overview
Stock performance and key metrics
4 upcoming, 0 past
SRPT Earnings Report
EPS Est: $0.34 | FQ end 2026-06 | Call: 2026-08-05 15:00:00
3 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How SRPT's past catalysts played out
SRP-9003
Limb-girdle Muscular Dystrophy
SRP-4045
Duchenne Muscular Dystrophy
Eteplirsen
Duchenne Muscular Dystrophy
RESTEN-MP
Coronary Artery Disease
AVI-4658 (Eteplirsen)
Duchenne Muscular Dystrophy (DMD)
AVI-4658 for Injection
Duchenne Muscular Dystrophy
SRP-4053
Duchenne Muscular Dystrophy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SRP-9003 | Phase 3 | Limb-girdle Muscular Dystrophy | - | - |
SRP-4045 | Phase 3 | Duchenne Muscular Dystrophy | - | - |
Eteplirsen | Phase 3 | Duchenne Muscular Dystrophy | - | - |
RESTEN-MP | Phase 2 | Coronary Artery Disease | - | - |
AVI-4658 (Eteplirsen) | Phase 2 | Duchenne Muscular Dystrophy (DMD) | - | - |
AVI-4658 for Injection | Phase 2 | Duchenne Muscular Dystrophy | - | - |
SRP-4053 | Phase 2 | Duchenne Muscular Dystrophy | - | - |
Duchenne Muscular Dystrophy
4 drugs in this indication
Coronary Artery Disease
1 drug in this indication
Limb-girdle Muscular Dystrophy
1 drug in this indication
Duchenne Muscular Dystrophy (DMD)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Sarepta Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 7 drug candidates in Sarepta Therapeutics, Inc.'s (SRPT) pipeline across Phase 3, Phase 2. Its lead program is SRP-9003 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Sarepta Therapeutics, Inc.'s next FDA catalyst?→
Sarepta Therapeutics, Inc.'s (SRPT) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SRPT biotech catalysts?→
Add SRPT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Sarepta Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.